2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Clinically Isolated Syndrome: new trials by email Literature Review of Clinically Isolated Syndrome trials Research Report on Clinically Isolated Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) PEG-liposomal prednisolone sodium phosphate, Methylprednisolone - Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 15 | 2009-12-01 | 2016-10-06 |
| Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis Tovaxin - Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome | Phase 2 | Terminated | Opexa Therapeutics, Inc. | 116 | 2007-11-01 | 2016-03-15 |
Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Multiple Sclerosis (1) · Nervous System Diseases (1)
Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · tovaxin (1)
Lakefront Biotherapeutics NV (1) · Opexa Therapeutics, Inc. (1)
Belgium (1) · Germany (1) · Poland (1) · United States (1)
Edward J Fox, MD, PhD (1) · Johan Beetens, PhD (1)
2009 (1)